Human Genome Epidemiology Literature Finder
Records 1 - 3 (of 3 Records) |
Query Trace: Fatigue and AXL[original query] |
---|
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Jan 31 (2): 181-6. Choueiri Toni K, Vaishampayan Ulka, Rosenberg Jonathan E, Logan Theodore F, Harzstark Andrea L, Bukowski Ronald M, Rini Brian I, Srinivas Sandy, Stein Mark N, Adams Laurel M, Ottesen Lone H, Laubscher Kevin H, Sherman Laurie, McDermott David F, Haas Naomi B, Flaherty Keith T, Ross Robert, Eisenberg Peter, Meltzer Paul S, Merino Maria J, Bottaro Donald P, Linehan W Marston, Srinivasan Ramapras |
Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. Expert review of clinical pharmacology 2015 Nov 1-11. Krajewska Jolanta, Olczyk Tomasz, Jarzab Barba |
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget 2017 Sep 8 (41): 69651-69662. Leighl Natasha B, Tsao Ming-Sound, Liu Geoffrey, Tu Dongsheng, Ho Cheryl, Shepherd Frances A, Murray Nevin, Goffin John R, Nicholas Garth, Sakashita Shingo, Chen Zhuo, Kim Lucia, Powers Jean, Seymour Lesley, Goss Glenwood, Bradbury Penelope |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source: